MX2021001613A - Anticuerpos anti-factor xi. - Google Patents
Anticuerpos anti-factor xi.Info
- Publication number
- MX2021001613A MX2021001613A MX2021001613A MX2021001613A MX2021001613A MX 2021001613 A MX2021001613 A MX 2021001613A MX 2021001613 A MX2021001613 A MX 2021001613A MX 2021001613 A MX2021001613 A MX 2021001613A MX 2021001613 A MX2021001613 A MX 2021001613A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- factor
- fxia
- fxi
- thrombosis
- Prior art date
Links
- 108010074864 Factor XI Proteins 0.000 abstract 3
- 108010080805 Factor XIa Proteins 0.000 abstract 3
- 208000007536 Thrombosis Diseases 0.000 abstract 2
- 102100030563 Coagulation factor XI Human genes 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/099638 WO2020029179A1 (en) | 2018-08-09 | 2018-08-09 | Anti-factor xi antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001613A true MX2021001613A (es) | 2021-04-28 |
Family
ID=69413757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001613A MX2021001613A (es) | 2018-08-09 | 2018-08-09 | Anticuerpos anti-factor xi. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3833692A1 (ko) |
| JP (1) | JP2021534098A (ko) |
| KR (1) | KR20210042352A (ko) |
| CN (4) | CN116554334A (ko) |
| AU (1) | AU2018436195A1 (ko) |
| BR (1) | BR112021002472A2 (ko) |
| CA (1) | CA3108708A1 (ko) |
| MX (1) | MX2021001613A (ko) |
| WO (1) | WO2020029179A1 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11958911B2 (en) | 2017-02-10 | 2024-04-16 | Shanghai Benemae Pharmaceutical | Anti-coagulation factor XI antibody |
| CN116554334A (zh) * | 2018-08-09 | 2023-08-08 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
| US20220089777A1 (en) * | 2019-01-21 | 2022-03-24 | Aronora, Inc. | Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effect and uses thereof |
| US20230343982A1 (en) | 2021-03-31 | 2023-10-26 | Lg Energy Solution, Ltd. | Mono-Cell Manufacturing Apparatus with Gloss Meter and Manufacturing Method Using the Same |
| CN116410258A (zh) * | 2023-04-13 | 2023-07-11 | 上海太阳生物技术有限公司 | 因子xi缺乏血浆保护剂及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014202009A1 (en) * | 2007-11-21 | 2014-05-01 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
| PT3002298T (pt) * | 2007-11-21 | 2019-11-20 | Univ Oregon Health & Science | Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos |
| TR201820051T4 (tr) * | 2008-06-19 | 2019-01-21 | Prothix Bv | Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması |
| DK2373691T3 (en) * | 2008-12-18 | 2019-04-15 | Oregon Health&Science Univ | ANTI-FXI ANTIBODIES AND PROCEDURES FOR USE |
| JP6348900B2 (ja) * | 2012-05-10 | 2018-06-27 | バイエル ファーマ アクチエンゲゼルシャフト | 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途 |
| JOP20200312A1 (ar) * | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| AU2017209083A1 (en) * | 2016-01-22 | 2018-07-12 | Adimab, Llc | Anti-coagulation factor XI antibodies |
| CA3018124A1 (en) * | 2016-03-23 | 2017-09-28 | Prothix Bv | Monoclonal antibodies against the active site of factor xi and uses thereof |
| CN108409863B (zh) * | 2017-02-10 | 2023-09-26 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
| CN116554334A (zh) * | 2018-08-09 | 2023-08-08 | 上海仁会生物制药股份有限公司 | 抗凝血因子xi抗体 |
-
2018
- 2018-08-09 CN CN202310301532.8A patent/CN116554334A/zh not_active Withdrawn
- 2018-08-09 KR KR1020217006922A patent/KR20210042352A/ko unknown
- 2018-08-09 AU AU2018436195A patent/AU2018436195A1/en not_active Abandoned
- 2018-08-09 CN CN202111466510.4A patent/CN114478781B/zh active Active
- 2018-08-09 JP JP2021506623A patent/JP2021534098A/ja active Pending
- 2018-08-09 BR BR112021002472-7A patent/BR112021002472A2/pt not_active Application Discontinuation
- 2018-08-09 WO PCT/CN2018/099638 patent/WO2020029179A1/en unknown
- 2018-08-09 CA CA3108708A patent/CA3108708A1/en not_active Abandoned
- 2018-08-09 MX MX2021001613A patent/MX2021001613A/es unknown
- 2018-08-09 CN CN201880098606.XA patent/CN113227150B/zh active Active
- 2018-08-09 EP EP18929685.8A patent/EP3833692A1/en not_active Withdrawn
- 2018-08-09 CN CN202111467365.1A patent/CN114478782B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114478781B (zh) | 2024-04-02 |
| KR20210042352A (ko) | 2021-04-19 |
| BR112021002472A2 (pt) | 2021-07-27 |
| CN114478781A (zh) | 2022-05-13 |
| WO2020029179A1 (en) | 2020-02-13 |
| CN114478782A (zh) | 2022-05-13 |
| JP2021534098A (ja) | 2021-12-09 |
| CA3108708A1 (en) | 2020-02-13 |
| CN114478782B (zh) | 2024-04-02 |
| CN113227150B (zh) | 2023-07-28 |
| EP3833692A1 (en) | 2021-06-16 |
| CN116554334A (zh) | 2023-08-08 |
| AU2018436195A1 (en) | 2021-02-18 |
| CN113227150A (zh) | 2021-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021001613A (es) | Anticuerpos anti-factor xi. | |
| MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| PH12019501973A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| MX2019005911A (es) | Anticuerpos anti_cd137 novedosos y usos de estos. | |
| PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
| PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
| GEP20237466B (en) | Methods of inhibiting angiogenesis in patient | |
| SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
| EA201691470A1 (ru) | Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека | |
| MX2019009500A (es) | Anticuerpos anti factor de coagulación xi. | |
| MX2020014031A (es) | Proteinas heterodimericas y usos de las mismas. | |
| MX2023010076A (es) | Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas. | |
| WO2019023315A3 (en) | RAC INHIBITORS | |
| MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
| MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| MX2019003077A (es) | Anticuerpos novedosos contra el factor xi y sus usos. | |
| MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
| MX2021012769A (es) | Anticuerpos bloqueadores cd73. | |
| MA40526A (fr) | Protéines de fixation antigénique fixant le cxcr3 | |
| MX2019013700A (es) | Composiciones y metodos para el tratamiento de complicaciones y trastornos que se relacionan con el factor de von willebrand. | |
| EP4218817A3 (en) | Methods for treating metabolic diseases by inhibiting myostatin activation | |
| MX2021002292A (es) | Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa. | |
| MX2021002286A (es) | Terapias de combinacion. |